Last Updated : May 1, 2025
Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Please scroll or swipe to the right to view the full content.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Mvasi | Bevacizumab | mCRC NSCLC Biosimilar | N/A | Complete | ||
| Myalepta | metreleptin | Leptin deficiency in lipodystrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Myfembree | relugolix, estradiol, and norethindrone acetate | Management of heavy menstrual bleeding associated with uterine fibroids | Active | |||
| Myfortic | Mycophenolate sodium | Organ rejection in allogeneic renal transplants, Prophylaxis | List in a similar manner to other drugs in class | Complete | ||
| Myinfla | colchicine | Atherothrombotic events in coronary artery disease | Do not reimburse | Complete | ||
| Mylotarg | Gemtuzumab Ozogamicin | Acute Myeloid Leukemia (AML) | Reimburse | Complete | ||
| Myozyme | Alglucosidase | Pompe's disease | List with clinical criteria and/or conditions | Complete | ||
| Myrbetriq | Mirabegron | Overactive bladder | Withdrawn | |||
| Myrbetriq | Mirabegron | Overactive bladder | List with criteria/condition | Complete | ||
| N/A | everolimus | Renal angiomyolipoma associated with tuberous sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | panitumumab | Left-sided metastatic colorectal cancer (mCRC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | nab-paclitaxel | Gastrointestinal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | eltrombopag | Severe Aplastic Anemia (SAA) | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | ibrutinib | Hematology | Received | |||
| N/A | guanfacine hydrochloride extended-release | Attention Deficit Hyperactivity Disorder (ADHD) | Pending | |||
| N/A | Aripiprazole | Depression | Received | |||
| N/A | trametinib | Gynecological cancers | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | blinatumomab | Acute lymphoblastic leukemia, pediatrics | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | Pembrolizumab | Melanoma (Skin) | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | Nivolumab and Ipilimumab | Melanoma (Skin) | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | Nab-paclitaxel | Solid tumours | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | Enzalutamide | Genito-urinary cancer (prostate cancer) | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | bevacizumab and lomustine | Recurrent glioblastoma multiform | Reimburse with clinical criteria and/or conditions | Complete | ||
| n/a | abiraterone acetate and prednisolone | High-risk non-metastatic prostate cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | rivaroxaban | Venous thromboembolic events (VTE) | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 1, 2025